Ovarian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms (∼ 80%)1; however, other less-common pathologic subtypes must be considered in treatment guidelines. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer discuss epithelial ovarian cancer (including borderline or low malignant potential) and less-common histopathologies, including malignant germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors of the ovary [MMMT]), and sex cord-stromal tumors. The guidelines also discuss fallopian tube and primary peritoneal cancers, which are less-common neoplasms that are managed similarly to epithelial ovarian cancer. However, the less-common histologies of ovarian cancer are managed differently. Information on the less-common ovarian histopathologies are not published in this issue of JNCCN, but can be found online at www.NCCN.org.Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the country's fifth most common cause of cancer mortality in women. In 2010, an estimated 21,900 new diagnoses and 13,900 deaths will occur from this neoplasm in the United States; fewer than 40% of women with ovarian cancer are cured.2,3 The incidence of ovarian cancer increases with age and is most prevalent in the eighth decade of life, with a rate of 57 per 100,000 women. The median age at diagnosis is 63 years, and 70% of patients present with advanced disease.4Epidemiologic studies have identified risk factors for ovarian cancer. A 30% to 60% decreased risk of cancer is associated...
  • 1.

    ChanJKCheungMKHusainA. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol2006;108:521528.

  • 2.

    JemalASiegelRXuJWardE. Cancer statistics, 2010. CA Cancer J Clin2010;60:277300.

  • 3.

    JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225249.

  • 4.

    FlemingGFRonnettBMSeidmanJ. Epithelial ovarian cancer. In: BarakatRRMarkmanMRandallME eds. Principles and Practice of Gynecologic Oncology 5th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2009:763836.

    • Search Google Scholar
    • Export Citation
  • 5.

    MorchLSLokkegaardEAndreasenAH. Hormone therapy and ovarian cancer. JAMA2009;302:298305.

  • 6.

    FinchABeinerMLubinskiJ. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA2006;296:185192.

    • Search Google Scholar
    • Export Citation
  • 7.

    RebbeckTRKauffNDDomchekSM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst2009;101:8087.

    • Search Google Scholar
    • Export Citation
  • 8.

    Clarke-PearsonDL. Clinical practice. Screening for ovarian cancer. N Engl J Med2009;361:170177.

  • 9.

    RohMHKindelbergerDCrumCP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?Am J Surg Pathol2009;33:376383.

    • Search Google Scholar
    • Export Citation
  • 10.

    CarlsonJWMironAJarboeEA. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol2008;26:41604165.

    • Search Google Scholar
    • Export Citation
  • 11.

    KindelbergerDWLeeYMironA. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol2007;31:161169.

    • Search Google Scholar
    • Export Citation
  • 12.

    MedeirosFMutoMGLeeY. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol2006;30:230236.

    • Search Google Scholar
    • Export Citation
  • 13.

    SemmelDRFolkinsAKHirschMS. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol2009;22:985988.

    • Search Google Scholar
    • Export Citation
  • 14.

    GoffBAMandelLSDrescherCW. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer2007;109:221227.

    • Search Google Scholar
    • Export Citation
  • 15.

    AndersenMRGoffBALoweKA. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer2008;113:484489.

  • 16.

    RossingMAWicklundKGCushing-HaugenKLWeissNS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst2010;24:222229.

    • Search Google Scholar
    • Export Citation
  • 17.

    MenonUGentry-MaharajAHallettR. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol2009;10:327340.

    • Search Google Scholar
    • Export Citation
  • 18.

    PartridgeEKreimerARGreenleeRT. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol2009;113:775782.

    • Search Google Scholar
    • Export Citation
  • 19.

    ValentinLJurkovicDVan CalsterB. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol2009;34:345354.

    • Search Google Scholar
    • Export Citation
  • 20.

    HartgeP. Designing early detection programs for ovarian cancer. J Natl Cancer Inst2010;102:34.

  • 21.

    HorvathGJarverudGAJarverudSHorvathI. Human ovarian carcinomas detected by specific odor. Integr Cancer Ther2008;7:7680.

  • 22.

    HorvathGChiloJLindbladT. Different volatile signals emitted by human ovarian carcinoma and healthy tissue. Future Oncol2010;6:10431049.

    • Search Google Scholar
    • Export Citation
  • 23.

    LuKHSkatesSBeversTB. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract 5003.

    • Search Google Scholar
    • Export Citation
  • 24.

    GiedeKCKieserKDodgeJRosenB. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol2005;99:447461.

    • Search Google Scholar
    • Export Citation
  • 25.

    EarleCCSchragDNevilleBA. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst2006;98:172180.

    • Search Google Scholar
    • Export Citation
  • 26.

    du BoisAQuinnMThigpenT. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol2005;16(Suppl 8):viii7viii12.

    • Search Google Scholar
    • Export Citation
  • 27.

    VisintinIFengZLongtonG. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res2008;14:10651072.

  • 28.

    DrapkinRvon HorstenHHLinY. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res2005;65:21622169.

    • Search Google Scholar
    • Export Citation
  • 29.

    NolenBVelikokhatnayaLMarrangoniA. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol2010;117:440445.

    • Search Google Scholar
    • Export Citation
  • 30.

    AndersonGLMcIntoshMWuL. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst2010;102:2638.

    • Search Google Scholar
    • Export Citation
  • 31.

    EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual 7th ed.New York, NY: Springer; 2010.

  • 32.

    ImSSGordonANButtinBM. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol2005;105:3541.

  • 33.

    ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol2007;110:201214.

  • 34.

    DearkingACAlettiGDMcGreeME. How relevant are ACOG and SGO guidelines for referral of adnexal mass?Obstet Gynecol2007;110:841848.

  • 35.

    TimmermanDTestaACBourneT. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol2008;31:681690.

    • Search Google Scholar
    • Export Citation
  • 36.

    IyerVRLeeSI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol2010;194:311321.

    • Search Google Scholar
    • Export Citation
  • 37.

    VergoteIDe BrabanterJFylesA. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet2001;357:176182.

    • Search Google Scholar
    • Export Citation
  • 38.

    DeVitaVTLawrenceTSRosenbergSADePinhoRA. DeVita Hellman and Rosenberg's Cancer: Principles & Practice of Oncology 8th ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 39.

    SchilderJMThompsonAMDePriestPD. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol2002;87:17.

    • Search Google Scholar
    • Export Citation
  • 40.

    FaderANRosePG. Role of surgery in ovarian carcinoma. J Clin Oncol2007;25:28732883.

  • 41.

    WrightJDShahMMathewL. Fertility preservation in young women with epithelial ovarian cancer. Cancer2009;115:41184126.

  • 42.

    SatohTHataeMWatanabeY. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol2010;28:17271732.

    • Search Google Scholar
    • Export Citation
  • 43.

    StierEABarakatRRCurtinJP. Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol1996;87:737740.

  • 44.

    EisenhauerELAbu-RustumNRSonodaY. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol2006;103:10831090.

    • Search Google Scholar
    • Export Citation
  • 45.

    du BoisAReussAPujade-LauraineE. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer2009;115:12341244.

    • Search Google Scholar
    • Export Citation
  • 46.

    BristowREPuriIChiDS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol2009;112:265274.

  • 47.

    AlettiGDDowdySCGostoutBS. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol2006;107:7785.

    • Search Google Scholar
    • Export Citation
  • 48.

    EisenhauerELAbu-RustumNRSonodaY. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol2008;108:276281.

    • Search Google Scholar
    • Export Citation
  • 49.

    PaniciPBMaggioniAHackerN. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst2005;97:560566.

    • Search Google Scholar
    • Export Citation
  • 50.

    AlettiGDPowlessCBakkum-GamezJ. Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. Gynecol Oncol2009;114:3236.

    • Search Google Scholar
    • Export Citation
  • 51.

    du BoisAReussAHarterP. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol2010;28:17331739.

    • Search Google Scholar
    • Export Citation
  • 52.

    WimbergerPLehmannNKimmigR. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol2007;106:6974.

    • Search Google Scholar
    • Export Citation
  • 53.

    RosePGNerenstoneSBradyMF. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med2004;351:24892497.

  • 54.

    van der BurgMEvan LentMBuyseM. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med1995;332:629634.

    • Search Google Scholar
    • Export Citation
  • 55.

    ColomboPEMourregotAFabbroM. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol2009;35:135143.

    • Search Google Scholar
    • Export Citation
  • 56.

    SteedHOzaAMMurphyJ. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int J Gynecol Cancer2006;16(Suppl 1):4753.

    • Search Google Scholar
    • Export Citation
  • 57.

    TangjitgamolSManusirivithayaSLaopaiboonMLumbiganonP. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev2009:CD006014.

    • Search Google Scholar
    • Export Citation
  • 58.

    TierstenADLiuPYSmithHO. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group study S0009. Gynecol Oncol2009;112:444449.

    • Search Google Scholar
    • Export Citation
  • 59.

    VandenputIVan CalsterBCapoenA. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?Br J Cancer2009;101:244249.

    • Search Google Scholar
    • Export Citation
  • 60.

    VergoteITropeCGAmantF. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med2010;363:943953.

  • 61.

    ArmstrongDKBundyBWenzelL. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med2006;354:3443.

  • 62.

    YoungRCWaltonLAEllenbergSS. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med1990;322:10211027.

    • Search Google Scholar
    • Export Citation
  • 63.

    MarkmanMWalkerJL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol2006;24:988994.

    • Search Google Scholar
    • Export Citation
  • 64.

    MarthCWalkerJLBarakatRR. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer2007;109:645649.

    • Search Google Scholar
    • Export Citation
  • 65.

    OzolsRFBundyBNGreerBE. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol2003;21:31943200.

    • Search Google Scholar
    • Export Citation
  • 66.

    VaseyPAJaysonGCGordonA. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst2004;96:16821691.

    • Search Google Scholar
    • Export Citation
  • 67.

    McGuireWPHoskinsWJBradyMF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med1996;334:16.

    • Search Google Scholar
    • Export Citation
  • 68.

    BellJBradyMFYoungRC. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol2006;102:432439.

    • Search Google Scholar
    • Export Citation
  • 69.

    KatsumataNYasudaMTakahashiF. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374:13311338.

    • Search Google Scholar
    • Export Citation
  • 70.

    MarkmanM. Management of ovarian cancer. An impressive history of improvement in survival and quality of life. Oncology (Williston Park)2006;20:347354.

    • Search Google Scholar
    • Export Citation
  • 71.

    WenzelLBHuangHQArmstrongDK. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol2007;25:437443.

    • Search Google Scholar
    • Export Citation
  • 72.

    MarkmanM. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. Cancer J2009;15:105109.

  • 73.

    ZeimetAGReimerDRadlAC. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res2009;29:28032808.

    • Search Google Scholar
    • Export Citation
  • 74.

    WalkerJLArmstrongDKHuangHQ. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol2006;100:2732.

    • Search Google Scholar
    • Export Citation
  • 75.

    GoreMdu BoisAVergoteI. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol2006;24:45284530.

  • 76.

    ArmstrongDKBradyMF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol2006;24:45314533.

  • 77.

    OzolsRFBookmanMAdu BoisA. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol2006;103:16.

    • Search Google Scholar
    • Export Citation
  • 78.

    BookmanMA. Dose-dense chemotherapy in advanced ovarian cancer. Lancet2009;374:13031305.

  • 79.

    BurgerRABradyMFBookmanMA. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study [abstract]. J Clin Oncol2010;28(Suppl 18):Abstract LBA1.

    • Search Google Scholar
    • Export Citation
  • 80.

    MobusVWandtHFrickhofenN. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol2007;25:41874193.

    • Search Google Scholar
    • Export Citation
  • 81.

    PapadimitriouCDafniUAnagnostopoulosA. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant2008;41:547554.

    • Search Google Scholar
    • Export Citation
  • 82.

    BookmanMABradyMFMcGuireWP. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol2009;27:14191425.

    • Search Google Scholar
    • Export Citation
  • 83.

    MarkmanMLiuPYWilczynskiS. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol2003;21:24602465.

    • Search Google Scholar
    • Export Citation
  • 84.

    CastellsMCTennantNMSloaneDE. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol2008;122:574580.

    • Search Google Scholar
    • Export Citation
  • 85.

    DizonDSSabbatiniPJAghajanianC. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol2002;84:378382.

    • Search Google Scholar
    • Export Citation
  • 86.

    SampsonHAMunoz-FurlongACampbellRL. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med2006;47:373380.

    • Search Google Scholar
    • Export Citation
  • 87.

    ManivannanVDeckerWWSteadLG. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med2009;2:35.

    • Search Google Scholar
    • Export Citation
  • 88.

    LenzHJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist2007;12:601609.

  • 89.

    GabizonAA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest2001;19:424436.

    • Search Google Scholar
    • Export Citation
  • 90.

    MarkmanMZanottiKPetersonG. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol2003;21:46114614.

    • Search Google Scholar
    • Export Citation
  • 91.

    LeeCWMatulonisUACastellsMC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol2005;99:393399.

    • Search Google Scholar
    • Export Citation
  • 92.

    LeeCWMatulonisUACastellsMC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol2004;95:370376.

    • Search Google Scholar
    • Export Citation
  • 93.

    MarkmanMHsiehFZanottiK. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol2004;130:2528.

    • Search Google Scholar
    • Export Citation
  • 94.

    CornBWLancianoRMBoenteM. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer1994;74:29792983.

    • Search Google Scholar
    • Export Citation
  • 95.

    TingerAWaldronTPelusoN. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys2001;51:12561263.

    • Search Google Scholar
    • Export Citation
  • 96.

    FulhamMJCarterJBaldeyA. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol2009;112:462468.

    • Search Google Scholar
    • Export Citation
  • 97.

    RisumSHogdallCMarkovaE. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer2009;19:600604.

    • Search Google Scholar
    • Export Citation
  • 98.

    AllardJSomersETheilRMooreRG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 5535.

    • Search Google Scholar
    • Export Citation
  • 99.

    RustinGJvan der BurgME. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) [abstract]. J Clin Oncol2009;27(Suppl 18S):Abstract 1.

    • Search Google Scholar
    • Export Citation
  • 100.

    MillerRERustinGJ. How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol2010;22:498502.

  • 101.

    MarkmanMPetersenJBellandABurgK. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial. Oncology2010;78:12.

    • Search Google Scholar
    • Export Citation
  • 102.

    KaramAKKarlanBY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol2010;7:335339.

  • 103.

    BastRCJr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer2010;116:28502853.

    • Search Google Scholar
    • Export Citation
  • 104.

    HatchKDBeechamJBBlessingJACreasmanWT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer1991;68:269271.

    • Search Google Scholar
    • Export Citation
  • 105.

    Van Der VeldenJGitschGWainGV. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer1995;5:301305.

  • 106.

    TherassePArbuckSGEisenhauerEA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000;92:205216.

    • Search Google Scholar
    • Export Citation
  • 107.

    MarkmanMBlessingJRubinSC. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol2006;101:436440.

    • Search Google Scholar
    • Export Citation
  • 108.

    SharmaRGrahamJMitchellH. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pretreated platinum-resistant recurrent ovarian cancer. Br J Cancer2009;100:707712.

    • Search Google Scholar
    • Export Citation
  • 109.

    MarkmanMRothmanRHakesT. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol1991;9:389393.

    • Search Google Scholar
    • Export Citation
  • 110.

    Fung-Kee-FungMOliverTElitL. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol2007;14:195208.

  • 111.

    ParmarMKLedermannJAColomboN. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet2003;361:20992106.

    • Search Google Scholar
    • Export Citation
  • 112.

    EisenkopSMFriedmanRLSpirtosNM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer2000;88:144153.

    • Search Google Scholar
    • Export Citation
  • 113.

    StraussHGHenzeATeichmannA. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol2007;104:612616.

    • Search Google Scholar
    • Export Citation
  • 114.

    KushnerDMConnorJPSanchezF. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol2007;105:358364.

    • Search Google Scholar
    • Export Citation
  • 115.

    RosePG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer2005;15(Suppl 1):1822.

    • Search Google Scholar
    • Export Citation
  • 116.

    PfistererJPlanteMVergoteI. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol2006;24:46994707.

    • Search Google Scholar
    • Export Citation
  • 117.

    Pujade-LauraineEWagnerUAavall-LundqvistE. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol2010;28:33233329.

    • Search Google Scholar
    • Export Citation
  • 118.

    GordonANTondaMSunSRackoffW. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol2004;95:18.

    • Search Google Scholar
    • Export Citation
  • 119.

    FerrandinaGLudovisiMLorussoD. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol2008;26:890896.

    • Search Google Scholar
    • Export Citation
  • 120.

    MutchDGOrlandoMGossT. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol2007;25:28112818.

    • Search Google Scholar
    • Export Citation
  • 121.

    RothenbergMLLiuPYWilczynskiS. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol2004;95:506512.

    • Search Google Scholar
    • Export Citation
  • 122.

    BajettaEDi LeoABiganzoliL. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol1996;14:25462551.

    • Search Google Scholar
    • Export Citation
  • 123.

    RosePGBlessingJAMayerARHomesleyHD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol1998;16:405410.

    • Search Google Scholar
    • Export Citation
  • 124.

    RosePGBlessingJABallHG. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol2003;88:130135.

    • Search Google Scholar
    • Export Citation
  • 125.

    MillerDSBlessingJAKrasnerCN. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol2009;27:26862691.

    • Search Google Scholar
    • Export Citation
  • 126.

    TenerielloMGTsengPCCrozierM. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol2009;27:14261431.

    • Search Google Scholar
    • Export Citation
  • 127.

    AlbertsDSJiangCLiuPY. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer2004;14:224228.

    • Search Google Scholar
    • Export Citation
  • 128.

    MarkmanMHakesTReichmanB. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol1992;10:243248.

    • Search Google Scholar
    • Export Citation
  • 129.

    BidusMAWebbJCSeidmanJD. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol2006;102:57.

    • Search Google Scholar
    • Export Citation
  • 130.

    WrightJDHagemannARaderJS. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer2006;107:8389.

    • Search Google Scholar
    • Export Citation
  • 131.

    BurgerRASillMWMonkBJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol2007;25:51655171.

    • Search Google Scholar
    • Export Citation
  • 132.

    CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol2007;25:51805186.

    • Search Google Scholar
    • Export Citation
  • 133.

    SimpkinsFBelinsonJLRosePG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol2007;107:118123.

    • Search Google Scholar
    • Export Citation
  • 134.

    FerrandinaGLudovisiMDe VincenzoR. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol2007;18:13481353.

    • Search Google Scholar
    • Export Citation
  • 135.

    WolfJKBodurkaDCVerschraegenC. A phase II trial of oral capecitabine in patients with platinum—and taxane— refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol2006;102:468474.

    • Search Google Scholar
    • Export Citation
  • 136.

    RaoGGMillerDS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther2006;6:4347.

  • 137.

    PapadimitriouCAMarkakiSSiapkarasJ. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology2004;66:112117.

    • Search Google Scholar
    • Export Citation
  • 138.

    BowmanAGabraHLangdonSP. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res2002;8:22332239.

    • Search Google Scholar
    • Export Citation
  • 139.

    del CarmenMGFullerAFMatulonisU. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol2003;91:596602.

    • Search Google Scholar
    • Export Citation
  • 140.

    RamirezPTSchmelerKMMilamMR. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol2008;110:5659.

    • Search Google Scholar
    • Export Citation
  • 141.

    AudehMWCarmichaelJPensonRT. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet2010;376:245251.

    • Search Google Scholar
    • Export Citation
  • 142.

    FongPCYapTABossDS. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol2010;28:25122519.

    • Search Google Scholar
    • Export Citation
  • 143.

    GelmonKAHirteHWRobidouxA. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract 3002.

    • Search Google Scholar
    • Export Citation
  • 144.

    MatsuoKEnoMLImDD. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol2010;116:6165.

    • Search Google Scholar
    • Export Citation
  • 145.

    KaramAKChiangJWFungE. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol2009;114:246252.

    • Search Google Scholar
    • Export Citation
  • 146.

    CadronILeunenKVan GorpT. Management of borderline ovarian neoplasms. J Clin Oncol2007;25:29282937.

  • 147.

    BarakatRRBenjaminILewisJLJr. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol1995;59:390393.

    • Search Google Scholar
    • Export Citation
  • 148.

    GershensonDMSilvaEG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer1990;65:578585.

  • 149.

    LeakeJFCurrieJLRosensheinNBWoodruffJD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol1992;47:150158.

    • Search Google Scholar
    • Export Citation
  • 150.

    BarnhillDRKurmanRJBradyMF. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol1995;13:27522756.

    • Search Google Scholar
    • Export Citation
  • 151.

    SuttonGPBundyBNOmuraGA. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol1991;41:230233.

    • Search Google Scholar
    • Export Citation
  • 152.

    KennedyAWHartWR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer1996;78:278286.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 364 364 28
PDF Downloads 55 55 6
EPUB Downloads 0 0 0